A carregar...
Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
RATIONALE: The treatment of non-small cell lung cancer (NSCLC) has now changed dramatically in recent years and anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitors are developing rapidly. PATIENT CONCERNS: Here we reported a 57-year-old ALK-positive NSCLC man with brain metastases. DIAGNOS...
Na minha lista:
Publicado no: | Medicine (Baltimore) |
---|---|
Main Authors: | , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Wolters Kluwer Health
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5690796/ https://ncbi.nlm.nih.gov/pubmed/29137103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000008652 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|